Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endocrinologists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Endocrinologists. Displaying page 1 of 1.
    EudraCT Number: 2014-002265-30 Sponsor Protocol Number: Infacort003 Start Date*: 2015-02-19
    Sponsor Name:Diurnal Limited
    Full Title: A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency.
    Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. Cu...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006352-36 Sponsor Protocol Number: VPN-10-18 Start Date*: 2013-04-11
    Sponsor Name:Lithuanian University of Health Sciences, Endocrinology Department
    Full Title: Obesity in children and adolescents: complications, associated risks and early intervention (lifestyle changes and insulin sensitivity improving medicine (metformin) effectiveness and safety evalua...
    Medical condition: The aim of our study is to establish the effectivenes and safety of metformin use in pediatric obese population; to assess the prevalence of insulin resistance, metabolic syndrome, polycystic ovary...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001826-61 Sponsor Protocol Number: 11‐HM10560A‐201 Start Date*: 2011-07-29
    Sponsor Name:Hanmi Pharmaceutical Co., Ltd.
    Full Title: A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone defic...
    Medical condition: Adult growth hormone deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-005375-91 Sponsor Protocol Number: NN9535-4216 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) DE (Completed) GB (Completed) SK (Completed) LV (Completed) LT (Completed) GR (Completed) ES (Completed) PT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005732-28 Sponsor Protocol Number: LE-9999-401-BE Start Date*: 2013-06-14
    Sponsor Name:Takeda Belgium
    Full Title: A multicentre, open-label switch study to investigate the necessity of dose adjustment after switching from L-Thyroxine Christiaens® to the new levothyroxine sodium test formulation in (near) total...
    Medical condition: Patient that underwent a near total thyroidectomy and therefore are compelled to take levothyroxine hormone substition therapy.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10043777 Thyroidectomy total LLT
    16.0 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004826-92 Sponsor Protocol Number: NN9535-3624 Start Date*: 2013-09-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) NL (Completed) FI (Completed) GR (Completed) GB (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004827-19 Sponsor Protocol Number: NN9535-3626 Start Date*: 2013-10-01
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BG (Completed) PT (Completed) ES (Completed) HU (Completed) CZ (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-004392-12 Sponsor Protocol Number: NN9535-3625 Start Date*: 2014-04-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SK (Completed) DE (Completed) GB (Completed) NL (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000904-27 Sponsor Protocol Number: NN9535-4269 Start Date*: 2017-05-30
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus. A 30-week randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000632-94 Sponsor Protocol Number: NN9535-3623 Start Date*: 2013-10-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004984-27 Sponsor Protocol Number: NN2211-3867 Start Date*: 2013-09-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) LV (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004502-26 Sponsor Protocol Number: NN9535-3627 Start Date*: 2014-09-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002696-41 Sponsor Protocol Number: NN2211-3917 Start Date*: 2012-06-19
    Sponsor Name:Novo Nordisk A/S
    Full Title: The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-002952-34 Sponsor Protocol Number: NN9924-4437 Start Date*: 2020-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 07:57:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA